MRK

Merck & Co., Inc. [MRK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MRK Stock Summary

Top 10 Correlated ETFs

MRK


Top 10 Correlated Stocks

MRK


In the News

03:43 28 Mar 2024 MRK

Three-Stock Lunch: Tesla, Merck, and RH

Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.

10:32 28 Mar 2024 MRK

Merck shares move higher as lung disorder drug secures ‘squeaky clean' label from FDA

Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food and Drug Administration (FDA) approval for its lung disorder drug sotatercept, brand name WINREVAIR.  After being granted breakthrough therapy designation by the agency, the drug is now the first FDA-approved activin signalling inhibitor therapy for pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening disease where the blood vessels in an individual's lungs thicken and narrow and cause strain on the heart.

10:19 28 Mar 2024 MRK

Merck Stock Nabs Record High After FDA Approval

Merck & Co Inc  (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constriction of lung arteries.

10:05 28 Mar 2024 MRK

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

09:41 28 Mar 2024 MRK

Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair

Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.

06:06 28 Mar 2024 MRK

Merck shares rise on FDA approval for Winrevair

Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.

05:11 28 Mar 2024 MRK

FDA approves Merck's drug for rare, deadly lung condition

The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.

05:11 28 Mar 2024 MRK

US FDA approves Merck's blood pressure therapy

The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio

05:07 28 Mar 2024 MRK

Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives

The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.

09:51 28 Mar 2024 MRK

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

MRK Financial details

Company Rating
Buy
Market Cap
313.67B
Income
365M
Revenue
60.11B
Book val./share
14.84
Cash/share
2.83
Dividend
3
Dividend %
2.28%
Employees
70K
Optionable
Yes
Shortable
Yes
Earnings
25 Apr 2024
P/E
914.31
Forward P/E
14.72
PEG
-93.89
P/S
5.55
P/B
8.88
P/C
46.66
P/FCF
36.5
Quick Ratio
0.71
Current Ratio
1.25
Debt / Equity
0.94
LT Debt / Equity
0.89
-
-
EPS (TTM)
0.15
EPS next Y
8.97
EPS next Q
2.06
EPS this Y
-97.56%
EPS next Y
5881.45%
EPS next 5Y
7749.61%
EPS last 5Y
-48.54%
Revenue last 5Y
5.03%
Revenue Q/Q
-8.34%
EPS Q/Q
-125.67%
-
-
-
-
SMA20
-0.78%
SMA50
7.63%
SMA100
23.3%
Inst Own
58.55%
Inst Trans
0.79%
ROA
-
ROE
1%
ROC
0.05%
Gross Margin
74%
Oper. Margin
6%
Profit Margin
1%
Payout
2040%
Shs Outstand
2.53B
Shs Float
2.53B
-
-
-
-
Target Price
118.74
52W Range
99.14-130.24
52W High
+1.58%
52W Low
+33.39%
RSI
76
Rel Volume
0.65
Avg Volume
8.48M
Volume
5.55M
Perf Week
6.63%
Perf Month
4.36%
Perf Quarter
27.13%
Perf Half Y
24.77%
-
-
-
-
Beta
0.384
-
-
Volatility
3.66%, 3.28%
Prev Close
0.24%
Price
132.06
Change
-0.61%

MRK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
18.4518.9719.2523.4123.6
Net income per share
3.882.795.165.730.14
Operating cash flow per share
5.294.055.587.545.13
Free cash flow per share
3.932.23.825.813.6
Cash per share
4.123.193.25.212.82
Book value per share
10.210.0115.0918.1614.81
Tangible book value per share
-3-3.73-2.351.81-0.62
Share holders equity per share
10.210.0115.0918.1614.81
Interest debt per share
10.7312.8913.412.514.38
Market cap
220.18B197.36B193.9B280.93B276.58B
Enterprise value
236.85B221.09B218.91B298.92B305.94B
P/E ratio
22.3727.9314.8619.35757.76
Price to sales ratio
4.74.113.984.744.62
POCF ratio
16.3819.2513.7414.7121.27
PFCF ratio
22.0935.4420.0719.130.25
P/B Ratio
8.57.85.086.117.36
PTB ratio
8.57.85.086.117.36
EV to sales
5.064.614.495.045.11
Enterprise value over EBITDA
18.3924.415.7916.0544.64
EV to operating cash flow
17.6221.5615.5215.6523.52
EV to free cash flow
23.7639.722.6620.3333.46
Earnings yield
0.040.040.070.050
Free cash flow yield
0.050.030.050.050.03
Debt to equity
1.021.260.870.670.94
Debt to assets
0.310.350.310.280.33
Net debt to EBITDA
1.292.621.80.974.28
Current ratio
1.241.021.271.471.25
Interest coverage
10.336.5413.2115.292.6
Income quality
1.371.451.141.3135.63
Dividend Yield
0.030.030.030.020.03
Payout ratio
0.580.880.510.4820.4
Sales general and administrative to revenue
0.190.180.160.130
Research and developement to revenue
0.210.280.250.230.51
Intangibles to total assets
0.40.380.420.380.37
Capex to operating cash flow
-0.26-0.46-0.32-0.23-0.3
Capex to revenue
-0.07-0.1-0.09-0.07-0.06
Capex to depreciation
-0.95-1.29-1.38-1.12-1
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
29.8325.0841.8548.416.92
ROIC
0.150.070.130.170.01
Return on tangible assets
0.190.120.210.210.01
Graham Net
-15.7-19.4-19.54-15.75-19.86
Working capital
5.26B437M6.39B11.48B6.47B
Tangible asset value
-7.62B-9.44B-5.94B4.59B-1.57B
Net current asset value
-30.91B-38.42B-37.17B-27.38B-36.87B
Invested capital
1.021.260.870.670.94
Average receivables
6.92B7.31B8.54B9.34B10.26B
Average payables
3.53B4.17B4.6B4.44B4.09B
Average inventory
5.71B6.14B6.13B5.93B6.13B
Days sales outstanding
52.8259.7169.1758.1867.5
Days payables outstanding
96.68108.29123.4689.3989.6
Days of inventory on hand
154.62148.73159.46123.92145.25
Receivables turnover
6.916.115.286.275.41
Payables turnover
3.783.372.964.084.07
Inventory turnover
2.362.452.292.952.51
ROE
0.380.280.340.320.01
Capex per share
-1.37-1.85-1.76-1.73-1.52

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
5.455.715.926.295.78
Net income per share
1.191.11-2.351.87-0.48
Operating cash flow per share
1.750.531.463.040.1
Free cash flow per share
1.290.131.082.69-0.29
Cash per share
5.24.12.533.472.83
Book value per share
18.1418.4515.2416.2614.84
Tangible book value per share
1.812.3-0.830.36-0.62
Share holders equity per share
18.1418.4515.2416.2614.84
Interest debt per share
12.1912.2114.6513.8714.07
Market cap
281.37B270.02B292.98B261.18B276.15B
Enterprise value
299.37B291.03B324.18B287.4B305.51B
P/E ratio
23.3223.93-12.2613.76-56.31
Price to sales ratio
20.3418.6419.4916.3618.88
POCF ratio
63.51201.6679.133.851.12K
PFCF ratio
85.76813.31106.9638.32-371.67
P/B Ratio
6.125.777.576.337.35
PTB ratio
6.125.777.576.337.35
EV to sales
21.6520.0921.5618.0120.88
Enterprise value over EBITDA
84.6675.14-66.6947.92449.94
EV to operating cash flow
67.58217.3587.5237.241.24K
EV to free cash flow
91.24876.58118.3642.17-411.18
Earnings yield
0.010.01-0.020.020
Free cash flow yield
0.0100.010.030
Debt to equity
0.670.660.950.850.94
Debt to assets
0.280.290.350.330.33
Net debt to EBITDA
5.095.42-6.424.3743.24
Current ratio
1.471.441.281.381.25
Interest coverage
11.2511.91-17.5518.92-0.96
Income quality
1.470.47-0.621.63-0.2
Dividend Yield
0.010.010.010.010.01
Payout ratio
0.580.66-0.320.39-1.51
Sales general and administrative to revenue
0.040000
Research and developement to revenue
0.270.30.890.210.6
Intangibles to total assets
0.380.380.390.380.37
Capex to operating cash flow
-0.26-0.75-0.26-0.12-4.02
Capex to revenue
-0.08-0.07-0.06-0.06-0.07
Capex to depreciation
-1.29-1.02-1.07-0.89-1.03
Stock based compensation to revenue
0.010.010.010.010.01
Graham number
22.0321.4828.4126.1612.71
ROIC
0.030.03-0.070.070
Return on tangible assets
0.040.04-0.090.07-0.02
Graham Net
-15.72-15.31-18.56-17.66-19.9
Working capital
11.48B10.27B6.58B8.86B6.47B
Tangible asset value
4.59B5.84B-2.12B918M-1.57B
Net current asset value
-27.38B-27.49B-35.75B-33.47B-36.87B
Invested capital
0.670.660.950.850.94
Average receivables
9.47B10.51B11.93B11.98B11.37B
Average payables
3.82B3.97B3.56B3.48B3.72B
Average inventory
5.76B5.89B5.9B6.03B6.24B
Days sales outstanding
61.571.9273.5565.8268.11
Days payables outstanding
98.8884.3676.9874.06105.68
Days of inventory on hand
137.08134.4132.63129.41171.32
Receivables turnover
1.461.251.221.371.32
Payables turnover
0.911.071.171.220.85
Inventory turnover
0.660.670.680.70.53
ROE
0.070.06-0.150.12-0.03
Capex per share
-0.45-0.4-0.38-0.36-0.39

MRK Frequently Asked Questions

What is Merck & Co., Inc. stock symbol ?

Merck & Co., Inc. is a US stock , located in Kenilworth of Nj and trading under the symbol MRK

Is Merck & Co., Inc. buy or a sell ?

32 stock analysts have 32 predictions with a medium analyst target price of $110.25. The lowest prediction is $76 and the highest is $294

What is MRK stock prediction ?

With a median analyst target price of $140.67, 3 stock analysts have made 3 forecasts in last 90 days. $135 is the lowest and $145 is the greatest projection.

What is Merck & Co., Inc. stock quote today ?

Merck & Co., Inc. stock price is $132.06 today.

Is Merck & Co., Inc. stock public?

Yes, Merck & Co., Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap